Neutrophil-to-lymphocyte ratio predicts long-term survival in early triple negative breast cancer treated with neoadjuvant chemotherapy
ecancermedicalscience · 14.11.2025 · 19
DOI: 10.3332/ecancer.2025.2034 ↗Kurz gefasst
Fachartikel in der Zeitschrift ecancermedicalscience, online erschienen am 14.11.2025. Verfasst von Gabriel Berlingieri Polho und 9 weiteren Autor:innen. Beteiligte Einrichtung: Instituto do Câncer do Estado de São Paulo, Av Dr Arnaldo, 251 - Cerqueira Cesar, São Paulo, SP 01246-000, Brazil. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Biomarkers for tailoring treatment in neoadjuvant triple-negative breast cancer (TNBC) are needed. We hypothesize that neutrophil-to-lymphocyte ratio (NLR) before neoadjuvant chemotherapy (NACT) can predict long-term outcomes in this population.
Methods
We reviewed our institutional database to identify patients with clinical stages II-III TNBC who underwent NACT from 2012 to 2024 and retrospectively collected data from medical records. We calculated event-free survival (EFS) from the date of NACT initiation until death, disease recurrence or disease progression that precluded surgery; we calculated overall survival (OS) from the date of NACT initiation until death. Survival estimates were analysed using Kaplan-Meier method and compared with log rank test. The Cox regression model was used to calculate hazard ratios.
Results
A total of 692 patients were included in the analysis. Of these, 63.3% had stage III disease, 60.8% had grade 3 tumours and 77.2% had a Ki-67 >50%. The most common NACT regimen used was anthracycline and taxane-based (96.8%). The overall pathological complete response (pCR) rate was 27.7%. After median follow-up of 59.6 months, NLR >2 was associated with poorer EFS (HR 1.71, 95% CI 1.33-2.18, p < 0.001) and OS (HR 1.76, 95% CI 1.34-2.31, p < 0.001). The results maintained statistical significance after adjusting for age, ki67, clinical stage and pCR status (p = 0.002).
Conclusion
NLR predicts long-term survival after NACT in TNBC and, as a readily and inexpensive information, should be further studied in current approaches of chemoimmunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto do Câncer do Estado de São Paulo, Av Dr Arnaldo, 251 - Cerqueira Cesar, São Paulo, SP 01246-000, Brazil.
- Dasa Oncology, Brasilia Hospital, SHIS QI 15 - Lago Sul, Brasília 71635-240, Brazil.
- Instituto D'Or de Pesquisa e Ensino (IDOR), Av Brigadeiro Luís Antônio, 5001 - Jardim Paulista, São Paulo, SP 22281-100, Brazil.
- https://orcid.org/0000-0001-5818-922X.
Zitieren
APA
Polho, G. B., Murazawa, L. K., Oliveira, V. V., Pinheiro, V. R., Del Cisne Pineda Labanda, D., Shinkado, Y. R., Barroso-Sousa, R., Barros, L. R. C., Testa, L., & Bonadio, R. C. (2025). Neutrophil-to-lymphocyte ratio predicts long-term survival in early triple negative breast cancer treated with neoadjuvant chemotherapy. ecancermedicalscience, 19. https://doi.org/10.3332/ecancer.2025.2034
Vancouver
Polho GB, Murazawa LK, Oliveira VV, Pinheiro VR, Del Cisne Pineda Labanda D, Shinkado YR, et al. Neutrophil-to-lymphocyte ratio predicts long-term survival in early triple negative breast cancer treated with neoadjuvant chemotherapy. ecancermedicalscience. 2025;19. doi:10.3332/ecancer.2025.2034
BibTeX
@article{Polho2025,
author = {Polho, Gabriel Berlingieri and Murazawa, Leticia Kimie and Oliveira, Vinicius Vitor and Pinheiro, Victor Rocha and Del Cisne Pineda Labanda, Diana and Shinkado, Yumi Ricucci and Barroso-Sousa, Romualdo and Barros, Luciana Rodrigues Carvalho and Testa, Laura and Bonadio, Renata Colombo},
title = {Neutrophil-to-lymphocyte ratio predicts long-term survival in early triple negative breast cancer treated with neoadjuvant chemotherapy},
journal = {ecancermedicalscience},
year = {2025},
volume = {19},
doi = {10.3332/ecancer.2025.2034}
}
EUVIMED